Dyslipidemia vs Mixed Hyperlipidemia: Key Distinctions
Dyslipidemia is the broad umbrella term for any abnormality in lipid metabolism, while mixed hyperlipidemia is a specific subtype characterized by concurrent elevations in both LDL cholesterol and triglycerides. 1, 2
Definitions and Clinical Significance
Dyslipidemia (General Term)
Dyslipidemia encompasses the entire spectrum of lipid abnormalities that can affect cardiovascular disease risk 2. This includes:
- Isolated hypercholesterolemia (elevated LDL-C only)
- Isolated hypertriglyceridemia (elevated triglycerides only)
- Isolated low HDL-C
- Mixed hyperlipidemia (combined elevations)
- Combined hyperlipidemia (a specific genetic form)
The term "dyslipidemia" simply indicates that lipid metabolism is disturbed in some way, whether through genetic predisposition, secondary causes (diabetes, hypothyroidism, medications), or environmental factors 2.
Mixed Hyperlipidemia (Specific Pattern)
Mixed hyperlipidemia represents a distinct clinical entity defined by simultaneous elevation of both cholesterol and triglycerides 1, 3. The specific criteria include:
- Moderate hypertriglyceridemia: typically 2-5 g/L (200-500 mg/dL)
- Elevated LDL-C: variable levels
- Often accompanied by low HDL-C (≤0.4 g/L or 40 mg/dL)
- Presence of small, dense LDL particles 3, 4
This pattern is particularly common in patients with type 2 diabetes and metabolic syndrome 1, 4.
Critical Management Differences
For General Dyslipidemia
Treatment is tailored to the specific lipid abnormality present. The approach varies dramatically based on which lipid parameter is elevated 1.
For Mixed Hyperlipidemia
LDL-C remains the priority treatment target even when triglycerides are elevated 1. This is crucial: the presence of mixed hyperlipidemia with moderate hypertriglyceridemia (<5 g/L) does not change the therapeutic management compared to isolated hypercholesterolemia 1.
The treatment algorithm follows this sequence 1:
First-line: Statin therapy targeting LDL-C goals based on cardiovascular risk
- High/very high risk: LDL-C <1 g/L (100 mg/dL) or <0.7 g/L (70 mg/dL)
- Dietary and lifestyle measures are particularly important for the triglyceride component
If LDL-C is on target but triglycerides remain 2-5 g/L: Consider adding a fibrate ONLY if:
- HDL-C is low (≤0.4 g/L)
- AND cardiovascular risk is high or very high
- Use fenofibrate (not gemfibrozil) if combining with statin 1
If LDL-C is NOT on target: Intensify statin therapy or add ezetimibe before addressing triglycerides 1
If triglycerides ≥5 g/L: First-line fibrate therapy to reduce pancreatitis risk, regardless of LDL-C 1
Common Pitfalls to Avoid
Do not treat the triglycerides first in mixed hyperlipidemia with moderate hypertriglyceridemia (<5 g/L). The atherogenicity of hypertriglyceridemia is less intense than hypercholesterolemia, and LDL-C reduction provides greater cardiovascular benefit 1.
Do not use gemfibrozil with statins due to significantly increased rhabdomyolysis risk (15-fold higher than fenofibrate-statin combinations) 5. Fenofibrate is the only fibrate that should be combined with statins 1.
Recognize that lipid patterns can fluctuate in conditions like familial combined hyperlipidemia, where patients may present with mixed hyperlipidemia, isolated hypercholesterolemia, isolated hypertriglyceridemia, or even normal lipids at different times 6.
Genetic Considerations
Recent genetic evidence shows that combined hyperlipidemia is genetically more similar to isolated hypertriglyceridemia than to isolated hypercholesterolemia 7. Both conditions show accumulation of common triglyceride-raising variants rather than LDL-C-related genetic variants. This polygenic nature distinguishes it from monogenic conditions like familial hypercholesterolemia 7, 6.